OncoMax is a private biotechnology company founded with the goal to develop and launch new therapeutic anti-cancer agents. The priority is given to search for new drug candidates in the therapeutic areas with high unmet need for health care efficacy. 
Company’s first product is OM-RCA-01, a humanized monoclonal antibody against Fibroblast Growth Factor Receptor 1 (FGFR1) — novel anticancer target.  FGFR1 is involved in numerous oncogenic processes including tumor angiogenesis, transition to invasive and metastatic states and development of resistance to the therapy. Possible indications for OM-RCA-01 include breast cancer, non-small cell lung cancer,  metastatic prostate cancer and renal cell carcinoma.
Since 2011 the company is a participant of Technology Platform “Medicine of the Future” and a resident of Skolkovo Biomedical Cluster. In late 2011 OncoMax attracted Skolkovo Foundation grant in the amount of 30 million rubles (~$1M). The same year, the company was nominated for "Foresight Health" as the best R & D-Company of the Year. The second round of investments in OncoMax has been awarded as the best deal of year 2011 in “venture and direct investment” nomination of Russian Investor Award 2012.
In 2013 the company received a special award "FIRST PRIZE" for the best research at EMUC-2013.



 Исследования осуществляются ООО «ОнкоМакс» при грантовой поддержке Фонда «Сколково».